Replacement therapies in hemophilia A and B – Efficacy of extended half-life products
Chairs: David Lillicrap (Canada), Pier Mannuccio Mannucci (Italy)
08.30
Real life data: real benefits. What have we achieved?
Pratima Chowdari (UK)
09.00
How to optimize the use of extended half-life products (PK analysis)
Alfonso Iorio (Canada)
Safety of replacement therapies (standard and novel) (Part I)
Chairs: Nicola Ciavarella (Italy), Maria Elisa Mancuso (Italy)
09.30
Which bleeding phenotype can we expect in severe hemophilia A previously untreated patients treated with non replacement therapies?
Karin Fijn van Draat (The Netherlands)
10.00
How safety of novel anti-hemophilic drugs should be approached. Known and unknown adverse effects
Flora Peyvandi (Italy)
10.30
Are Fc – FVIII products less immunogenic? New clinical data?
Christoph Königs (Germany)
11.00
Break
Safety of replacement therapies (standard and novel) (Part II)
Chairs: Giovanni Di Minno (Italy), Mauro Biffoni (Italy)
11.30
Long-term side-effects of pegylated products: facts or fancies?
Silvio Garattini (Italy)
12.00
European pharmacovigilance of new products (with special emphasis on pegylated products)
Anneliese Hilger (EMA, Germany)
12.30
Immunogenicity of subcutaneous and intravenous drugs
David Lillicrap (Canada)
Lunch Satellite Symposium:
Evolution by design: advancing the standard of care in hemophilia A
Sponsored by Bayer
13.00
(not accredited for CME)
Chair: Erik Berntorp (Sweden)
How evolution leads to revolution in hemophilia care
Erik Berntorp (Sweden)
Advances driven by evolution: investigating the role of FVIII in coagulation and beyond
Hermann Eichler (Germany)
Advances driven by design: using real-life practice to guide clinical studies (results from PROTECT VIII)
Elena Santagostino (Italy)
Q&A and close
Satellite Symposium:
ADAMTS13 and VWF: progressing patient care through protein innovation
Sponsored by Takeda
14.00
(not accredited for CME)
Chair: Flora Peyvandi (Italy)
Welcome and introduction
Flora Peyvandi (Italy)
The ADAMTS13-Von Willebrand Factor (VWF) interaction: clinical implications & applications
Peter Lenting (France)
Congenital Thrombotic Thrombocytopenic Purpura (cTTP) as a chronic disease: what is the long-term view to achieve more optimal outcomes?
Paul Coppo (France)
The role of VWF in individualized care for patients with VWD
Andreas Tiede (Germany)
Panel discussion
All speakers
Facilitated by Flora Peyvandi (Italy)
Meeting summary and close
Flora Peyvandi (Italy)
Satellite Lecture:
VWF and FVIII: An Unending Love Affair
Sponsored by Kedrion
15.00
(not accredited for CME)
Chair: Prasad Mathew (USA)
Setting the stage
Prasad Mathew (USA)
Clinical Implications of this love story for patients with Hemophilia A
Maria Elisa Mancuso (Italy)
Q & A
All
15.30
Break
16.00
Keynote Lecture “Choice of assays for novel anti-hemophilic therapies”
Armando Tripodi (Italy)
Chair: Wolfgang Schramm (Germany)
The role of von Willebrand factor in factor VIII immunogenicity
Chairs: Giancarlo Castaman (Italy), Augusto B. Federici (Italy)
16.30
FVIII peptide presentation to the immune system; modulation by von Willebrand factor
Jan Voorberg (The Netherlands)
17.00
High von Willebrand factor affinity FVIII and immunogenicity
Peter Lenting (France)
17.30
Walking Poster Session
VIEW ePOSTER PROGRAMME
